Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration
NCT ID: NCT05999383
Last Updated: 2026-01-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
48 participants
INTERVENTIONAL
2025-07-01
2028-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Behavioral Pharmacology of Cannabis and Nicotine
NCT04124432
Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream
NCT06334016
E-cigarette Cessation in Adults Who Co-use Cannabis
NCT06688539
Cannabidiol for Reducing Cigarette Use
NCT06218056
Varenicline for Co-occurring Cannabis and Tobacco Use
NCT04595318
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Each study day will consist of a standardized session of 5 puffs of one of 8 study conditions using a PAX-3 vaporizer (PAX Labs, Inc.). Blood will be sampled multiple times for plasma THC, nicotine, and catecholamines, questionnaires administered for sensory and subjective effects, and heart rate, skin blood flow, and skin temperature will be measured. After 6 hours of abstinence, participants will have 60 minutes of ad libitum access to the assigned study condition, during which heart rate and blood pressure will be continuously monitored, blood sampled before and after for THC, nicotine, and platelet aggregation measured, and questionnaires administered.
Studies will be conducted at the Clinical \& Translational Science Institute (CTSI) Clinical Research Services-supported research ward at Zuckerberg San Francisco General.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo marijuana and regular cigarette
Participants will vape a 50/50 mixture of placebo marijuana (0% THC) and regular cigarette (25.94 mg/g nicotine content)
Nicotine
Participants will vape Regular and Very Low Nicotine content cigarettes from the PAX device
Pax Loose Leaf Vaporizer
In all arms, participants will be using the PAX Loose Leave Vaporizer.
Placebo Marijuana
Participants will vape placebo marijuana from the PAX device
Placebo marijuana and Very Low Nicotine Content cigarette
Participants will vape a 50/50 mixture of placebo marijuana (0% THC) and Very Low Nicotine Content cigarette (0.42 mg/g nicotine content)
Nicotine
Participants will vape Regular and Very Low Nicotine content cigarettes from the PAX device
Pax Loose Leaf Vaporizer
In all arms, participants will be using the PAX Loose Leave Vaporizer.
Placebo Marijuana
Participants will vape placebo marijuana from the PAX device
Medium marijuana and regular cigarette
Participants will vape a 50/50 mixture of medium marijuana (\<5% THC) and regular cigarette (25.94 mg/g nicotine content)
Cannabis
Participants will vape marijuana in varying doses from the PAX device
Nicotine
Participants will vape Regular and Very Low Nicotine content cigarettes from the PAX device
Pax Loose Leaf Vaporizer
In all arms, participants will be using the PAX Loose Leave Vaporizer.
Medium marijuana and Very Low Nicotine Content cigarette
Participants will vape a 50/50 mixture of medium marijuana (\<5% THC) and Very Low Nicotine Content cigarette (0.42 mg/g nicotine content)
Cannabis
Participants will vape marijuana in varying doses from the PAX device
Nicotine
Participants will vape Regular and Very Low Nicotine content cigarettes from the PAX device
Pax Loose Leaf Vaporizer
In all arms, participants will be using the PAX Loose Leave Vaporizer.
High marijuana and regular cigarette
Participants will vape a 50/50 mixture of high marijuana (\>10% THC) and regular cigarette (25.94 mg/g nicotine content)
Cannabis
Participants will vape marijuana in varying doses from the PAX device
Nicotine
Participants will vape Regular and Very Low Nicotine content cigarettes from the PAX device
Pax Loose Leaf Vaporizer
In all arms, participants will be using the PAX Loose Leave Vaporizer.
High marijuana and Very Low Nicotine Content cigarette
Participants will vape a 50/50 mixture of high marijuana (\>10% THC) and Very Low Nicotine Content cigarette (0.42 mg/g nicotine content)
Cannabis
Participants will vape marijuana in varying doses from the PAX device
Nicotine
Participants will vape Regular and Very Low Nicotine content cigarettes from the PAX device
Pax Loose Leaf Vaporizer
In all arms, participants will be using the PAX Loose Leave Vaporizer.
High marijuana only
Participants will vape high marijuana (\>10% THC)
Cannabis
Participants will vape marijuana in varying doses from the PAX device
Pax Loose Leaf Vaporizer
In all arms, participants will be using the PAX Loose Leave Vaporizer.
Regular cigarette only
Participants will vape a regular cigarette (25.94 mg/g nicotine content)
Nicotine
Participants will vape Regular and Very Low Nicotine content cigarettes from the PAX device
Pax Loose Leaf Vaporizer
In all arms, participants will be using the PAX Loose Leave Vaporizer.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cannabis
Participants will vape marijuana in varying doses from the PAX device
Nicotine
Participants will vape Regular and Very Low Nicotine content cigarettes from the PAX device
Pax Loose Leaf Vaporizer
In all arms, participants will be using the PAX Loose Leave Vaporizer.
Placebo Marijuana
Participants will vape placebo marijuana from the PAX device
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Systolic Blood Pressure \< 160 and \> 90\*
* Diastolic Blood Pressure \< 100 and \> 50\*
\*Considered out of range if both machine and manual readings are above/below these thresholds.
* Body Mass Index (BMI) ≤ 38.0 (at investigator's discretion for higher BMI if no other concurrent health issues)
* Current regular user of cannabis who smokes or vapes cannabis or THC extracts at least three days a week for the past 3 months or more
* Test positive for D-9-tetrahydrocannabinol (THC) at screening and self-report of cannabis use
* Current user of inhaled forms of tobacco/nicotine (cigarette, cigars, e-cigarettes) who use the product daily for the past 3 months or more
* Saliva cotinine ≥ 30 ng/mL
Exclusion Criteria
* Heart disease
* Seizures
* Cancer
* Thyroid disease (okay if controlled with medication)
* Diabetes
* Hepatitis B or C or Liver disease
* Glaucoma
* Kidney disease or urinary retention
* An ulcer in the past year
* Active use of an inhaler for asthma or Chronic Obstructive Pulmonary Disease (COPD)
* Hypertension if uncontrolled (meaning participant has a diagnosis, but they are not taking medication/under treatment (e.g., diet or exercise plan)
* Drug/Alcohol Dependence
* Alcohol or illicit drug dependence within the past 12 months (currently in treatment) with the exception of those who recently completed an alcohol/drug treatment program
* Positive toxicology test at the screening visit (THC \& prescribed medications okay)
* Opioid replacement therapy (including methadone, buprenorphine, or other)
* Psychiatric conditions
* Current or past schizophrenia, and/or current or past bipolar disorder
* Major depression, current or within the past year
* Major personality disorder
* Participants with current or past minor or moderate depression and/or anxiety disorders will be reviewed by the PI \[study physician\] and considered for inclusion
* History of psychiatric hospitalizations are not exclusionary, but study participation will be determined as per PI's \[study physician's\] approval
* Current regular use of any psychiatric medications with the exception of Selective serotonin reuptake inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRI) and current evaluation by the PI that the participant is otherwise healthy, stable, and able to participate
* Congenital or acquired immunodeficiency disorders (i.e. HIV, congenital immune deficiency syndrome, chronic diseases)
* Other disorders (i.e. ICU, malnutrition, immunosuppressive therapy)
* Traumatic brain injury
* Recent onset or change (worsening) in cough, fever and/or abdominal symptoms (vomiting or pain) in the past two weeks
* Medications
* Use of medications that are inducers of nicotine metabolizing enzyme CYP2A6 (Example: rifampicin, dexamethasone, phenobarbital, and other anticonvulsant drugs)
* Concurrent use of nicotine-containing medications
* Any stimulant medications (ex. Adderall) generally given for attention deficit hyperactivity disorder (ADHD) treatment
* Other/Misc. Chronic Health Problems
* Oral thrush
* Fainting
* Other "life threatening illnesses" as per study physician's discretion
* Pregnancy
* Pregnancy (self-reported and urine pregnancy test)
* Breastfeeding (determined by self-report)
* Concurrent participation in another clinical trial
* Inability to communicate in English
* History of marijuana-induced psychosis or paranoia after smoking marijuana
* Scoring a 7 or higher on the Severity of Dependence Scale (SDS) for cannabis use
* Planning to quit smoking or vaping within the next 60 days
* Planning to quit cannabis use within the next 60 days
* Uncomfortable with getting blood drawn
* Willingness to abstain from tobacco smoking and all combustible products for 13 hours before admission
* Willingness to abstain from smoking/ingestion of cannabis 13 hours before
* Willingness to abstain from nicotine products 13 hours before each admission
21 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
National Institutes of Health (NIH)
NIH
Food and Drug Administration (FDA)
FED
University of California, San Francisco
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gideon St Helen
Role: PRINCIPAL_INVESTIGATOR
University of California, San Francisco
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zuckerberg San Francisco General Hospital
San Francisco, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
23-38884
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.